UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stake in CareDx, Inc (NASDAQ:CDNA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in CareDx, Inc (NASDAQ:CDNA - Free Report) by 124.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 120,347 shares of the company's stock after buying an additional 66,833 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.22% of CareDx worth $2,577,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Sterling Capital Management LLC increased its stake in shares of CareDx by 771.2% in the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after acquiring an additional 1,126 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of CareDx by 553.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after acquiring an additional 3,322 shares during the period. State of Wyoming acquired a new stake in shares of CareDx in the fourth quarter worth $91,000. Plato Investment Management Ltd increased its stake in shares of CareDx by 34.1% in the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock worth $116,000 after acquiring an additional 1,370 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in shares of CareDx by 41.5% in the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company's stock worth $200,000 after acquiring an additional 2,742 shares during the period.

CareDx Stock Performance

Shares of NASDAQ:CDNA traded up $0.13 during midday trading on Tuesday, hitting $19.85. The company's stock had a trading volume of 1,166,906 shares, compared to its average volume of 910,550. The business's 50 day simple moving average is $17.39 and its 200 day simple moving average is $20.36. The company has a market cap of $1.11 billion, a P/E ratio of -7.35 and a beta of 2.18. CareDx, Inc has a 12-month low of $13.18 and a 12-month high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.03. The firm had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company's revenue for the quarter was up 17.6% on a year-over-year basis. During the same period last year, the firm posted ($0.03) earnings per share. On average, sell-side analysts predict that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CDNA has been the topic of several analyst reports. HC Wainwright restated a "neutral" rating and set a $25.00 price target on shares of CareDx in a research report on Monday, May 5th. Stephens reaffirmed an "overweight" rating and set a $40.00 price objective on shares of CareDx in a report on Monday, May 5th. Wall Street Zen downgraded shares of CareDx from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Finally, The Goldman Sachs Group decreased their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $30.33.

Insider Transactions at CareDx

In other CareDx news, Director Peter Maag sold 13,281 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total value of $228,831.63. Following the transaction, the director now directly owns 316,743 shares in the company, valued at $5,457,481.89. The trade was a 4.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director William A. Hagstrom sold 30,000 shares of the business's stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $17.45, for a total transaction of $523,500.00. Following the completion of the transaction, the director now owns 53,979 shares in the company, valued at $941,933.55. The trade was a 35.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 89,382 shares of company stock valued at $1,458,009. Corporate insiders own 4.40% of the company's stock.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.